Balloon-Expandable Versus Self-Expanding Prostheses for Transcatheter Treatment of Patients With Low-Flow, Low-Gradient Aortic Stenosis Germano Junior Ferruzzi, Michele Bellino, Angelo Silverio, Francesco Saia, Antonio Giulio Bruno, Paride Boragine, Andrea Buono, Maria Luisa De Rosa, Francesco Paolo Cancro, Italo Porto, Gabriele Crimi, Paolo Calabrò, Elisabetta Moscarella, Alfonso Ielasi, Carolina Montonati, Marco De Carlo, Alessandro Sticchi, Francesca Lanni, Francesca Maria Di Muro, Francesco Maiellaro, Ivan Francesco Calchera, Giacomo Boccuzzi, Antonio Sorropago, Fernando Scudiero, Tiziana Attisano, Rodolfo Citro, Giovanni Granata, Giuseppe De Luca, Giuseppe Musumeci, Gennaro Galasso, the LOW‐TAVR Investigators Journal of the American Heart Association, 2026 Background The use of balloon‐expandable valves (BEVs) or self‐expanding valves (SEVs) for transcatheter aortic valve replacement (TAVR) in patients with low‐flow, low‐gradient aortic stenosis (LFLG‐AS) has been poorly investigated. Aim of this study is to evaluate the procedural and clinical outcomes of patients with severe low‐flow, low‐gradient aortic stenosis undergoing TAVR with current‐generation prostheses. Methods This registry‐based, multicenter, cohort study included consecutive patients with low‐flow, low‐gradient aortic stenosis undergoing TAVR from January 2019 to December 2024 at 17 high‐volume Italian centers. The study population was divided into 2 groups according to the use of BEVs or SEVs. The primary outcome was all‐cause mortality up to 1 year. Results The study involved 1380 patients; 592 (42.9%) underwent TAVR with BEVs, and 788 (57.1%) with SEVs. At discharge, BEVs were linked to higher mean transvalvular gradients ( P <0.001) and a higher percentage of moderate predicted patient‐prosthesis mismatch ( P <0.001) compared with SEVs. After propensity score weighting, the Cox analysis showed no difference for the risk of the primary outcome (adjusted hazard ratio [HR]:1.23; 95% CI: 0.88–1.72), cardiovascular mortality (adjusted HR:1.37; 95% CI: 0.94–1.97), stroke (adjusted HR:1.83; 95% CI: 0.85–3.95), and myocardial infarction (adjusted HR:1.03; 95% CI: 0.40–2.69) between groups; however, the use of BEVs was associated with a significantly higher risk for HF hospitalization up to 1 year (adjusted HR: 1.54; 95% CI:1.05–2.25). Conclusions In this real‐world study on TAVR treatment for patients with low‐flow, low‐gradient aortic stenosis, there was no difference in mortality rates between BEVs and SEVs up to 1 year. However, the use of BEVs was linked to less favorable hemodynamic performance and a higher risk of HF hospitalization. Registration URL: https://clinicaltrials.gov/ ; Unique identifier: NCT06589063.
Prognostic impact of high-risk plaque morphology and impaired physiology in untreated non-culprit coronary lesions: a systematic review and meta-analysis Vincenzo Acerbo, Arturo Cesaro, Flavio Giuseppe Biccirè, Vincenzo De Sio, Antonio Capolongo, Maria Grazia Monaco, Elisabetta Moscarella, Felice Gragnano, Francesco Pelliccia, Francesco Prati, Dobromir Dobrev, Paolo Calabrò Ijc Heart and Vasculature, 2026 Background: The management of angiographically intermediate coronary lesions (AICLs) remains challenging. Although current guidelines recommend physiological assessment to guide treatment decisions, residual atherothrombotic risk related to vulnerable plaque morphology may persist in deferred non-culprit lesions (NCLs). We performed a systematic review and meta-analysis to evaluate the prognostic impact of high-risk plaque morphology and impaired physiology in untreated NCLs. Methods: A systematic search of PubMed, Embase, and Web of Science identified 10 studies that included both morphological (optical coherence tomography [OCT], intravascular ultrasound [IVUS], or near infrared spectroscopy) and physiological (fractional flow reserve [FFR], instantaneous wave-free ratio, quantitative flow ratio [QFR], Murray fractal law-based QFR, optical flow reserve, OCT-FFR, or IVUS-FFR) assessment in the same untreated AICLs. Overall, 4757 patients with 7662 untreated NCLs were stratified into four groups: reference, morphology-positive, functional-positive, and morpho-functional-positive. The primary endpoint was target vessel failure (TVF), defined as a composite of cardiac death, target-vessel myocardial infarction, and target-vessel revascularization. Hazard ratios (HRs) were pooled using random-effects models. Results: Compared with the reference group, TVF risk was increased in morphology-positive lesions (HR 2.94, 95% confidence interval [CI] 2.22-3.90) and functional-positive lesions (HR 3.59, 95% CI 1.56-8.24). The highest risk was observed in the morpho-functional-positive group. Indirect comparison showed no significant difference between morphology-positive and functional-positive lesions. Conclusions: High-risk plaque morphology and impaired physiology were independently associated with adverse outcomes in untreated NCLs, while their coexistence identified lesions at highest risk. An integrated morpho-functional assessment may improve risk stratification in multivessel coronary artery disease.
Global variability in bicuspid aortic valve morphology and aortopathy among patients with severe aortic stenosis referred for transcatheter valve implantation Alfonso Ielasi, Elisabetta Moscarella, Monica Barki, Rodolfo Caminiti, Sanjeev Bhatt, Giulio Guagliumi, Paolo Calabrò, Maurizzio Tespili Heart, 2026 Background While some studies have investigated the characteristics of patients from Asian versus European regions with bicuspid aortic valve (BAV) disease undergoing transcatheter aortic valve implantation (TAVI), geographic differences in a worldwide population remain poorly understood. The aim of our study was to evaluate the geographic differences of aortic valve morphology, annular size and associated aortopathy in a large, diverse population of India, West Europe, East Europe, Latin America, Middle East, Russia Commonwealth of Independent States, Asia Pacific and Africa patients with severe aortic stenosis (AS) referred for TAVI. Methods Data from cardiovascular multislice CT of severe AS patients referred for TAVI were analysed in a centralised core laboratory. Differences in valvular phenotype, annular size and aortic morphology were analysed with a focus on BAV patients. Results Among 12 712 patients evaluated, 3203 (25%) had BAV. These patients were more frequently male, younger and had larger annular area, aortic root diameters and higher prevalence of horizontal aorta (23% vs 10%, p<0.01) and severe calcifications (52% vs 32%, p<0.01). The highest prevalence of BAV was observed in patients from India (43%), with this group also being the youngest while the lowest was in patients from African regions (7%). Type 1 BAV was the most common (71%), followed by type 0 (26%) and type 2 (3%) subsets. Aortopathy was common across all geographic regions, but smaller aortic valve complex dimensions and lower coronary ostia height were seen in patients from India and the Asia-Pacific region. Eccentricity index and horizontal aorta were similar across different geographic regions. Conclusions BAV morphology and annular size showed significant heterogeneity based on the geographical origin. These differences may be relevant for procedural planning and anatomical assessment in BAV patients undergoing TAVI worldwide.
GISE/ANMCO/SIC Consensus document on the implementation of the new recommendations for the use of coronary functional testing and intravascular imaging in coronary angioplasty for chronic coronary syndromes Giulia Masiero, Cristina Aurigemma, Simone Biscaglia, Francesco Bruno, Francesco Burzotta, et al. Giornale Italiano Di Cardiologia, 2025 Chronic coronary syndromes require an integrated diagnostic-therapeutic approach that combines anatomical, functional, and morphological assessments. The 2024 ESC guidelines assign a key role to intravascular imaging and invasive coronary functional testing to guide percutaneous coronary revascularization and to reduce major adverse cardiovascular events, including cardiac death, myocardial infarction, and repeat revascularization - particularly in patients with complex anatomy - or to reduce angina class/improve quality of life in cases of epicardial and/or microvascular vascular dysfunction. However, the implementation of these strategies in Italy remains limited, characterized by significant geographical disparities and lower utilization rates compared to other European and international countries. Cultural, educational, managerial, and economic barriers continue to hinder the large-scale adoption of these technologies, despite their proven effectiveness in reducing major cardiovascular events. The aim of this GISE/ANMCO/SIC consensus document is to promote a more appropriate and systematic use of functional evaluation and intracoronary imaging in Italian clinical practice, through shared pathways for cultural awareness, training in catheterization laboratories, adjustment of reimbursement systems, and quality monitoring, in order to improve the appropriateness and personalization of care as well as long-term outcomes for patients with chronic coronary syndromes.
Correction to: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI) (Cardiovascular Diabetology, (2024), 23, 1, (420), 10.1186/s12933-024-02504-8) Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Roberto Scarsini, Luca Bergamaschi, Leonardo Portolan, Matteo Armillotta, Giuseppe Esposito, Elisabetta Moscarella, Giovanni Benfari, Claudio Montalto, Monika Shumkova, Elayne Kelen de Oliveira, Francesco Angeli, Mateusz Orzalkiewicz, Margherita Fabroni, Nurcan Baydaroglu, Andrea Raffaele Munafò, Daniele Oreste D’Atri, Matteo Casenghi, Lucia Scisciola, Michelangela Barbieri, Raffaele Marfella, Felice Gragnano, Edoardo Conte, Dario Pellegrini, Alfonso Ielasi, Daniele Andreini, Martin Penicka, Jacopo Andrea Oreglia, Paolo Calabrò, Antonio Bartorelli, Carmine Pizzi, Tullio Palmerini, Marc Vanderheyden, Francesco Saia, Flavio Ribichini, Emanuele Barbato Cardiovascular Diabetology, 2025 Correction: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Roberto Scarsini, Luca Bergamaschi, Leonardo Portolan, Matteo Armillotta, Giuseppe Esposito, Elisabetta Moscarella, Claudio Montalto, Elayne Kelen de Oliveira, Francesco Angeli, Mateusz Orzalkiewicz, Margherita Fabroni, Verdiana Galli, Nurcan Baydaroglu, Francesca Di Lenarda, Pasquale Policastro, Carlo Terrone, Davide Ausiello, Giose Vincelli, Matteo Casenghi, Lucia Scisciola, Raffaele Marfella, Felice Gragnano, Edoardo Conte, Dario Pellegrini, Alfonso Ielasi, Daniele Andreini, Jacopo Andrea Oreglia, Paolo Calabrò, Antonio L. Bartorelli, Tullio Palmerini, Francesco Saia, Flavio Ribichini, Michelangela Barbieri, Marc Vanderheyden, Carmine Pizzi, Emanuele Barbato Cardiovascular Diabetology, 2025 BACKGROUND: Acute kidney injury (AKI) following transcatheter aortic valve implantation (TAVI) is associated with significantly worse outcomes, leading to increased short- and long-term mortality. We sought to evaluate the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the risk of AKI in patients with type 2 diabetes mellitus (T2DM) and severe aortic stenosis (AS) undergoing TAVI. METHODS: Multicenter international registry of consecutive T2DM patients with severe AS undergoing TAVI between 2021 and 2024. The study population was stratified by the presence of chronic kidney disease (CKD), defined according to the KDIGO guideline, and anti-diabetic therapy at hospital admission (SGLT2i versus no-SGLT2i users). AKI was defined according to the Valve Academy Research Consortium 3 (VARC-3) criteria. RESULTS: The study population consisted of 514 patients stratified into those without CKD (n = 226, 44%), of whom 43 (19%) were treated with SGLT2i, and 288 (56%) with CKD, of whom 71 (24.7%) were on SGLT2i treatment. The median age was 81 [77-84] years, and 60.1% were males. SGLT2i use did not impact renal function in patients without CKD, with AKI occurring in 7.1% of the cases, regardless of SGLT2i use. Among CKD patients, AKI occurred more frequently in no-SGLT2i users compared to those receiving SGLT2i (19.8% versus 8.5%, p = 0.027), with a significant increase in post-TAVI and discharge serum creatinine values for no-SGLT2i users (p = 0.001 after TAVI and p < 0.001 at hospital discharge). Only in the CKD group, the use of SGLT2i was identified as an independent predictor of a lower rate of AKI (OR 0.70, 95%CI 0.42-0.91, p = 0.014). Patients who developed AKI had a higher incidence of major adverse cardiovascular events during follow-up, regardless of CKD (p < 0.025 for both groups). CONCLUSION: In diabetic patients with CKD undergoing TAVI, SGLT2i therapy was associated with a lower occurrence of AKI compared to those not treated with SGLT2i, suggesting a potential nephroprotective effect in this high-risk population.
Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction: Three-Year Outcomes of a Randomized Clinical Trial Simone Biscaglia, Andrea Erriquez, Vincenzo Guiducci, Javier Escaned, Raul Moreno, Valerio Lanzilotti, Andrea Santarelli, Enrico Cerrato, Giorgio Sacchetta, Alberto Menozzi, Ignacio Amat-Santos, José Luis Díez Gil, Marco Ruozzi, Marco Barbierato, Luca Fileti, Andrea Picchi, Rita Pavasini, Paolo Cimaglia, Iginio Colaiori, Gianni Casella, Mila Menozzi, Caterina Cavazza, Giorgio Caretta, Roberto Scarsini, Gianpiero D’Amico, Giuseppe Vadalà, Gerlando Pilato, Elisabetta Moscarella, Matteo Tebaldi, Gianluca Campo JAMA Cardiology, 2025 Importance Complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been shown to reduce cardiovascular death and MI at 1 year. However, the durability of this benefit over longer follow-up periods has been questioned by recent studies. Objective To determine whether the benefit of physiology-guided complete treatment, compared with culprit-only treatment, is sustained at 3 years in older patients with MI and multivessel disease. Design, Setting, and Participants This randomized clinical trial, Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE), was an investigator-initiated, multicenter, prospective, superiority trial conducted at 34 centers across 3 countries from July 18, 2019, to October 25, 2021. Participants were patients with MI (either ST segment or non–ST segment elevated) and multivessel disease who were hospitalized after successful treatment of the culprit lesion. Major exclusion criteria included a nonculprit lesion in the left main coronary artery and unclear identification of the culprit lesion. Data analysis was performed from March to May 2025. Interventions Culprit-only treatment or physiology-guided complete revascularization of nonculprit lesions. Main Outcomes and Measures The primary outcome was a patient-oriented composite end point of death, MI, stroke, or ischemia-driven revascularization. Secondary end points included a composite of cardiovascular death or MI and rate of heart failure hospitalizations. Results Among 1445 patients enrolled in the trial, the median (IQR) age was 80 (77-84) years; 917 patients were male (63.5%) and 528 female (36.5%). At 3 years, the primary outcome occurred in 165 patients (22.9%) in the physiology-guided complete revascularization group and 216 patients (29.8%) in the culprit-only group (hazard ratio [HR], 0.72; 95% CI, 0.58-0.88; P = .002). The key secondary outcome of cardiovascular death or MI occurred in a significantly lower number of patients in the physiology-guided complete revascularization group (92 patients [12.8%]) compared with the culprit-only group (132 patients [18.2%]; HR, 0.66; 95% CI, 0.50-0.88; P = .004). Hospitalizations for heart failure were more frequent in the culprit-only group compared with the physiology-guided complete group (143 [19.7%] vs 103 [14.3%]; HR, 0.73; 95% CI, 0.54-0.97; P = .03). Conclusions and Relevance In patients 75 years or older with MI and multivessel disease, the benefit of physiology-guided complete revascularization over culprit-lesion–only treatment was sustained at 3 years. Trial Registration ClinicalTrials.gov Identifier: NCT03772743
Balloon-Expandable Myval Octacor Versus Self-Expanding Evolut PRO/PRO+ and Acurate Neo2: Short-Term Outcomes From Propensity-Matched Analysis Elisabetta Moscarella, Alfonso Ielasi, Won‐Keun Kim, Rodolfo Caminiti, Marco Barbanti, Arturo Giordano, Andreas Holzamer, Luca Testa, Marianna Adamo, Amnon Eitan, Rodrigo Estévez‐Loureiro, Mihajlo Farkic, Nikolay Stoyanov, Juergen Leick, Mila Kovacevic, Eike Tigges, Antonio Mangieri, Andrea Scotti, Azeem Latib Catheterization and Cardiovascular Interventions, 2025 BackgroundWith transcatheter aortic valve implantation (TAVI) now extending to lower‐risk and younger patients, optimizing procedural and hemodynamic outcomes is critical. The Myval Octacor, a new balloon‐expandable valve (BEV), was developed to improve outcomes by reducing paravalvular regurgitation (PVL), minimizing pacemaker implantation (PPI) rates, and enhancing hemodynamic performance. However, limited data are available comparing Myval Octacor to contemporary self‐expanding supra‐annular valves (SEVs) Evolut PRO/PRO+ and Acurate Neo2.AimsThis study aimed to compare the safety, efficacy, and short‐term clinical outcomes of Myval Octacor with SEVs in transfemoral TAVI patients.MethodsWe conducted a prospective, multicenter registry including patients treated with Myval Octacor, then compared them to SEV recipients from the NEOPRO2 registry. Propensity score matching adjusted for baseline differences between groups. The primary endpoint was 30‐day Valve Academic Research Consortium‐3 (VARC‐3) device success. Secondary endpoints included technical success, valve performance, and early safety outcomes.ResultsAmong 252 Myval Octacor patients and 2175 SEV patients, 90 matched pairs were compared. Myval Octacor patients showed higher 30‐day VARC‐3 device success than SEVs patients (97% vs. 88%, p = 0.024), primarily due to a numerically lower rate of moderate‐to‐severe PVL (1% vs. 7%, p = 0.06). The Octacor group also exhibited larger indexed effective orifice areas. Mortality, stroke, PPI, and myocardial infarction rates were similar between groups at 30 days.ConclusionsThe Myval Octacor demonstrated comparable early safety and efficacy to supra‐annular SEVs, with advantages in device success rate and hemodynamic performance. Adequately sized randomized study is required to confirm these findings.
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention Antonio Capolongo, Vincenzo De Sio, Felice Gragnano, Mattia Galli, Natale Guarnaccia, Pasquale Maddaluna, Giuseppe Verde, Vincenzo Acerbo, Pierre Sabouret, Daniele Giacoppo, Matteo Conte, Silvio Coletta, Vincenzo Diana, Michelangelo Luciani, Elisabetta Moscarella, Arturo Cesaro, Francesco Pelliccia, Paolo Calabrò Journal of Clinical Medicine, 2025 The optimal long-term antithrombotic treatment of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains controversial. Current guidelines recommend a short initial period of triple antithrombotic therapy (e.g., 1 week), followed by dual therapy consisting of an oral anticoagulation agent and a single antiplatelet agent for 6 months in patients undergoing elective PCI and 12 months in patients with acute coronary syndromes. After this course of combination therapy, anticoagulation monotherapy is recommended. In daily practice, however, the optimal strategy for long-term antithrombotic therapy remains debated. A growing body of evidence supports the safety and efficacy of oral anticoagulation monotherapy, but its use in clinical practice remains inconsistent. This review aims to evaluate the available evidence on chronic antithrombotic regimens in patients with AF undergoing PCI, with a focus on key clinical considerations, such as the selection of optimal long-term therapy that balances ischemic and bleeding risks. It also highlights that, despite robust supporting evidence, significant gaps persist in real-world implementation.
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome Vincenzo De Sio, Felice Gragnano, Antonio Capolongo, Natale Guarnaccia, Pasquale Maddaluna, Vincenzo Acerbo, Mattia Galli, Martina Berteotti, Simona Sperlongano, Arturo Cesaro, Elisabetta Moscarella, Francesco Pelliccia, Giuseppe Patti, Emilia Antonucci, Plinio Cirillo, Pasquale Pignatelli, Gualtiero Palareti, Vittorio Pengo, Paolo Gresele, Rossella Marcucci, Paolo Calabrò International Journal of Cardiology, 2025
Antithrombotic therapy in complex percutaneous coronary intervention Domenico Simone Castiello, Angelo Oliva, Giuseppe Andò, Giampaolo Niccoli, Francesco Pelliccia, Elisabetta Moscarella, Rocco Antonio Montone, Felice Gragnano, Italo Porto, Paolo Calabrò, Salvatore De Rosa, Carmen Anna Maria Spaccarotella, Enrico Fabris, Giovanni Esposito, Ciro Indolfi, Gianfranco Sinagra, Pasquale Perrone Filardi, Raffaele Piccolo, Working Group of Interventional Cardiology of Italian Society of Cardiology Eurointervention, 2025
Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions Vincenzo De Sio, Felice Gragnano, Arturo Cesaro, Elisabetta Moscarella, Natale Guarnaccia, Antonio Capolongo, Pasquale Maddaluna, Giuseppe Verde, Vincenzo Acerbo, Gianmaria Scherillo, Pierre Sabouret, Daniele Giacoppo, Mattia Galli, Giuseppe Gargiulo, Giovanni Esposito, Marco Valgimigli, Dominick J. Angiolillo, Paolo Calabrò Expert Review of Cardiovascular Therapy, 2025
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI) Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Roberto Scarsini, Luca Bergamaschi, Leonardo Portolan, Matteo Armillotta, Giuseppe Esposito, Elisabetta Moscarella, Giovanni Benfari, Claudio Montalto, Monika Shumkova, Elayne Kelen de Oliveira, Francesco Angeli, Mateusz Orzalkiewicz, Margherita Fabroni, Nurcan Baydaroglu, Andrea Raffaele Munafò, Daniele Oreste D’Atri, Matteo Casenghi, Lucia Scisciola, Michelangela Barbieri, Raffaele Marfella, Felice Gragnano, Edoardo Conte, Dario Pellegrini, Alfonso Ielasi, Daniele Andreini, Martin Penicka, Jacopo Andrea Oreglia, Paolo Calabrò, Antonio Bartorelli, Carmine Pizzi, Tullio Palmerini, Marc Vanderheyden, Francesco Saia, Flavio Ribichini, Emanuele Barbato Cardiovascular Diabetology, 2024
Sudden cardiac death after early-onset myocardial infarction: a multicentre longitudinal cohort study with a 20-year follow-up Serena Bricoli, Giulia Magnani, Maddalena Ardissino, Giuseppe Maglietta, Patrizia Celli, Maurizio Ferrario, Umberto Canosi, Carlo Cernetti, Francesco Negri, Piera Angelica Merlini, Marco Tubaro, Carlo Berzuini, Chiara Manzalini, Luigi Moschini, Elisabetta Ponte, Roberto Pozzi, Silvia Buratti, Andrea Botti, Federico Barocelli, Andrea Biagi, Rosario Bonura, Luca Bearzot, Tiziano Moccetti, Antonio Crocamo, Maria Francesca Notarangelo, Elisabetta Moscarella, Paolo Calabrò, Giampaolo Niccoli, Diego Ardissino European Heart Journal Acute Cardiovascular Care, 2024
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions Rocco A. Montone, Riccardo Rinaldi, Giampaolo Niccoli, Giuseppe Andò, Felice Gragnano, Raffaele Piccolo, Francesco Pelliccia, Elisabetta Moscarella, Marco Zimarino, Enrico Fabris, Salvatore de Rosa, Paolo Calabrò, Italo Porto, Francesco Burzotta, Francesco Grigioni, Emanuele Barbato, Alaide Chieffo, Davide Capodanno, Rasha Al-Lamee, Tom J. Ford, Salvatore Brugaletta, Ciro Indolfi, Gianfranco Sinagra, Pasquale Perrone Filardi, Filippo Crea Journal of the American College of Cardiology, 2024
Health-Status Outcomes in Older Patients with Myocardial Infarction: Physiology-Guided Complete Revascularization Versus Culprit-Only Strategy Gianluca Campo, Vincenzo Guiducci, Javier Escaned, Raul Moreno, Gianni Casella, Caterina Cavazza, Enrico Cerrato, Marco Contarini, Marco Arena, Andres Iniguez Romo, Enrique Gutiérrez Ibañes, Roberto Scarsini, Giuseppe Vadalà, Giuseppe Andò, Gerlando Pilato, Sergio Musto d’Amore, Alessandro Capecchi, Ramiro Trillo Nouche, Elisabetta Moscarella, Alfonso Gambino, Marco Pavani, Anna Zanetti, Nicola Pesenti, Dariusz Dudek, Emanuele Barbato, Matteo Tebaldi, Simone Biscaglia Circulation Cardiovascular Quality and Outcomes, 2024
QFR for the Revascularization of Nonculprit Vessels in MI Patients: Insights From the FIRE Trial Andrea Erriquez, Gianluca Campo, Vincenzo Guiducci, Gianni Casella, Mila Menozzi, Enrico Cerrato, Giorgio Sacchetta, Raul Moreno, Marco Arena, Ignacio Amat Santos, Jose Luis Diez Gil, Roberto Scarsini, Marco Ruozzi, Manfredi Arioti, Andrea Picchi, Marco Barbierato, Elisabetta Moscarella, Sergio Musto D’Amore, Valerio Lanzilotti, Caterina Cavazza, Marco Rezzaghi, Marta Cocco, Andrea Marrone, Filippo Maria Verardi, Javier Escaned, Emanuele Barbato, Iginio Colaiori, Nicola Pesenti, Greta Carrara, Simone Biscaglia Jacc Cardiovascular Interventions, 2024
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine Felice Gragnano, Antonio Capolongo, Fabrizia Terracciano, Vincenzo De Sio, Pasquale Maddaluna, Fabio Fimiani, Elisabetta Moscarella, Arturo Cesaro, Rocco A. Montone, Roberto Bianco, Danilo Lisi, Mario Massimo Mensorio, Angela Annecchiarico, Paolo Calabrò Expert Review of Cardiovascular Therapy, 2023
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options Arturo Cesaro, Gianantonio De Michele, Fabio Fimiani, Vincenzo Acerbo, Gianmaria Scherillo, Giovanni Signore, Francesco Paolo Rotolo, Francesco Scialla, Giuseppe Raucci, Domenico Panico, Felice Gragnano, Elisabetta Moscarella, Olga Scudiero, Cristina Mennitti, Paolo Calabrò Frontiers in Cardiovascular Medicine, 2023
Severely calcified coronary artery lesions: focus on interventional management Giuseppe Andò, Giulia Alagna, Salvatore De Rosa, Francesco Pelliccia, Felice Gragnano, Giampaolo Niccoli, Raffaele Piccolo, Elisabetta Moscarella, Enrico Fabris, Rocco Antonio Montone, Saverio Muscoli, Carmen Spaccarotella, Gianfranco Sinagra, Ciro Indolfi, Italo Porto, Pasquale Perrone Filardi, Paolo Calabrò Vessel Plus, 2023
Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis Francesca Dongiglio, Emanuele Monda, Giuseppe Palmiero, Federica Verrillo, Marta Rubino, Gaetano Diana, Annapaola Cirillo, Adelaide Fusco, Erica Vetrano, Michele Lioncino, Martina Caiazza, Giuseppe Cerciello, Laura Capodicasa, Flavia Chiosi, Vincenzo Simonelli, Maria Luisa De Rimini, Francesco Natale, Alessandro Di Santo, Elisabetta Moscarella, Paolo Calabrò, Giuseppe Limongelli Journal of Clinical Medicine, 2023
Sex-Related Differences in Long-Term Outcomes After Early-Onset Myocardial Infarction Maddalena Ardissino, Adam J. Nelson, Giuseppe Maglietta, Guidantonio Malagoli Tagliazucchi, Caterina Disisto, Patrizia Celli, Maurizio Ferrario, Umberto Canosi, Carlo Cernetti, Francesco Negri, Piera Angelica Merlini, Marco Tubaro, Carlo Berzuini, Chiara Manzalini, Gianfranco Ignone, Carlo Campana, Luigi Moschini, Elisabetta Ponte, Roberto Pozzi, Raffaela Fetiveau, Silvia Buratti, Elvezia Maria Paraboschi, Rosanna Asselta, Andrea Botti, Domenico Tuttolomondo, Federico Barocelli, Serena Bricoli, Andrea Biagi, Rosario Bonura, Tiziano Moccetti, Antonio Crocamo, Giorgio Benatti, Giorgia Paoli, Emilia Solinas, Maria Francesca Notarangelo, Elisabetta Moscarella, Paolo Calabrò, Stefano Duga, Giulia Magnani, Diego Ardissino Frontiers in Cardiovascular Medicine, 2022
Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry Elisabetta Moscarella, Antonio Mangieri, Francesco Giannini, Didier Tchetchè, Won-Keun Kim, Jan-Malte Sinning, Uri Landes, Ran Kornowski, Ole De Backer, Georg Nickenig, Chiara De Biase, Lars Søndergaard, Federico De Marco, Francesco Bedogni, Marco Ancona, Matteo Montorfano, Damiano Regazzoli, Giulio Stefanini, Stefan Toggweiler, Corrado Tamburino, Sebastiano Immè, Giuseppe Tarantini, Horst Sievert, Ulrich Schäfer, Jörg Kempfert, Jochen Wöehrle, Azeem Latib, Paolo Calabrò, Massimo Medda, Maurizio Tespili, Antonio Colombo, Alfonso Ielasi International Journal of Cardiology, 2022
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease Paolo Calabrò, Felice Gragnano, Giampaolo Niccoli, Rossella Marcucci, Marco Zimarino, Carmen Spaccarotella, Giulia Renda, Giuseppe Patti, Giuseppe Andò, Elisabetta Moscarella, Massimo Mancone, Arturo Cesaro, Gennaro Giustino, Raffaele De Caterina, Roxana Mehran, Davide Capodanno, Marco Valgimigli, Stephan Windecker, George D. Dangas, Ciro Indolfi, Dominick J. Angiolillo, and Circulation, 2021
Impact of sglt2 inhibitors on heart failure: From pathophysiology to clinical effects Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, Pia Clara Pafundi, Raffaele Galiero, Alfredo Caturano, Elisabetta Moscarella, Felice Gragnano, Teresa Salvatore, Luca Rinaldi, Paolo Calabrò, Ferdinando Carlo Sasso International Journal of Molecular Sciences, 2021
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry Felice Gragnano, Elisabetta Moscarella, Paolo Calabrò, Arturo Cesaro, Pia Clara Pafundi, Alfonso Ielasi, Giuseppe Patti, Ilaria Cavallari, Emilia Antonucci, Plinio Cirillo, Pasquale Pignatelli, Gualtiero Palareti, Francesco Pelliccia, Carlo Gaudio, Ferdinando Carlo Sasso, Vittorio Pengo, Paolo Gresele, Rossella Marcucci, Fabio Fimiani, Raffaella Antonia Vitale, Alessandra Schiavo, Marzia Conte, Dario Di Maio, Daniele Pastori, Danilo Menichelli, Guido Grossi, Luigi Di Serafino, Vittorio Taglialatela, Raffaele Galiero, Carlo Acierno, Maurizio del Pinto, Giuseppe Gugliemini, and Internal and Emergency Medicine, 2021
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination Olga Scudiero, Barbara Lombardo, Mariarita Brancaccio, Cristina Mennitti, Arturo Cesaro, Fabio Fimiani, Luca Gentile, Elisabetta Moscarella, Federica Amodio, Annaluisa Ranieri, Felice Gragnano, Sonia Laneri, Cristina Mazzaccara, Pierpaolo Di Micco, Martina Caiazza, Giovanni D’Alicandro, Giuseppe Limongelli, Paolo Calabrò, Raffaela Pero, Giulia Frisso International Journal of Environmental Research and Public Health, 2021
Molecular basis of inflammation in the pathogenesis of cardiomyopathies Emanuele Monda, Giuseppe Palmiero, Marta Rubino, Federica Verrillo, Federica Amodio, Francesco Di Fraia, Roberta Pacileo, Fabio Fimiani, Augusto Esposito, Annapaola Cirillo, Adelaide Fusco, Elisabetta Moscarella, Giulia Frisso, Maria Giovanna Russo, Giuseppe Pacileo, Paolo Calabrò, Olga Scudiero, Martina Caiazza, Giuseppe Limongelli International Journal of Molecular Sciences, 2020
Childhood obesity: An overview of laboratory medicine, exercise and microbiome Olga Scudiero, Raffaela Pero, Annaluisa Ranieri, Daniela Terracciano, Fabio Fimiani, Arturo Cesaro, Luca Gentile, Eleonora Leggiero, Sonia Laneri, Elisabetta Moscarella, Cristina Mazzaccara, Giulia Frisso, Giovanni D’Alicandro, Giuseppe Limongelli, Lucio Pastore, Paolo Calabrò, Barbara Lombardo Clinical Chemistry and Laboratory Medicine, 2020
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes Mariarita Brancaccio, Cristina Mennitti, Sonia Laneri, Adelaide Franco, Margherita G. De Biasi, Arturo Cesaro, Fabio Fimiani, Elisabetta Moscarella, Felice Gragnano, Cristina Mazzaccara, Giuseppe Limongelli, Giulia Frisso, Barbara Lombardo, Chiara Pagliuca, Roberta Colicchio, Paola Salvatore, Paolo Calabrò, Raffaela Pero, Olga Scudiero Antibiotics, 2020
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry Elisabetta Moscarella, Alfonso Ielasi, Alessandro Beneduce, Giuseppe Ferrante, Carlo Andrea Pivato, Mauro Chiarito, Alberto Cappelletti, Giulia Perfetti, Valeria Magni, Eugenio Prati, Stefania Falcone, Adele Pierri, Stefano De Martini, Matteo Montorfano, Rosario Parisi, David Rutigliano, Nicola Locuratolo, Angelo Anzuini, Paolo Calabrò, Maurizio Tespili, Alberto Margonato, Alberto Benassi, Carlo Briguori, Franco Fabbiocchi, Bernhard Reimers, Antonio Bartorelli, Antonio Colombo, Cosmo Godino Catheterization and Cardiovascular Interventions, 2019
One-year clinical outcomes after unrestricted implantation of the Absorb bioresorbable scaffold (RAI registry) Alfonso Ielasi, Bernardo Cortese, Elisabetta Moscarella, Bruno Loi, Giuseppe Tarantini, Attilio Varricchio, Francesco Pisano, Alessandro Durante, Giampaolo Pasquetto, Alessandro Colombo, Gabriele Tumminello, Luciano Moretti, Paolo Calabrò, Pietro Mazzarotto, Maurizio Tespili, Pedro Silva Orrego, Donatella Corrado, Giuseppe Steffenino Eurointervention, 2018
Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry) Elisabetta Moscarella, Alfonso Ielasi, Attilio Varricchio, Maria Carmen De Angelis, Bruno Loi, Giuseppe Tarantini, Paolo Calabrò, Bernardo Cortese, Pietro Mazzarotto, Gabriele Gabrielli, Francesco Pisano, Michela Facchin, Leonardo Misuraca, Valerio Lucci, Roberto Gistri, Gabriele Tumminello, Luciano Moretti, Alessandro Colombo, Alessandro Durante, Massimo Fineschi, Davide Piraino, Maurizio Ferrario, Sebastian Coscarelli, Annamaria Nicolino, Maurizio Tespili, Donatella Corrado, Giuseppe Steffenino International Journal of Cardiology, 2018
Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Prospective RAI Registry) Bernardo Cortese, Alfonso Ielasi, Elisabetta Moscarella, Bruno Loi, Giuseppe Tarantini, Francesco Pisano, Alessandro Durante, Giampaolo Pasquetto, Alessandro Colombo, Gabriele Tumminello, Luciano Moretti, Paolo Calabrò, Pietro Mazzarotto, Attilio Varricchio, Maurizio Tespili, Roberto A. Latini, Gianfranco Defilippi, Donatella Corrado, Giuseppe Steffenino American Journal of Cardiology, 2017
Multi-step percutaneous treatment of post-myocardial infarction ventricular septal defects: A case report and review of literature Giornale Italiano Di Cardiologia, 2017
